![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MT2A |
Gene summary for MT2A |
![]() |
Gene information | Species | Human | Gene symbol | MT2A | Gene ID | 4502 |
Gene name | metallothionein 2A | |
Gene Alias | MT-2 | |
Cytomap | 16q13 | |
Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | P02795 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4502 | MT2A | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.21e-03 | 5.21e-01 | 0.0588 |
4502 | MT2A | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.87e-02 | 3.61e-01 | 0.294 |
4502 | MT2A | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 4.12e-06 | 1.31e+00 | 0.3487 |
4502 | MT2A | A002-C-010 | Human | Colorectum | FAP | 2.32e-03 | -1.37e-01 | 0.242 |
4502 | MT2A | A001-C-108 | Human | Colorectum | FAP | 6.07e-04 | -1.58e-01 | -0.0272 |
4502 | MT2A | A002-C-114 | Human | Colorectum | FAP | 3.98e-03 | -1.71e-01 | -0.1561 |
4502 | MT2A | A001-C-203 | Human | Colorectum | FAP | 3.23e-03 | -1.14e-01 | -0.0481 |
4502 | MT2A | A002-C-116 | Human | Colorectum | FAP | 1.23e-02 | -1.28e-01 | -0.0452 |
4502 | MT2A | F034 | Human | Colorectum | FAP | 1.97e-04 | -1.58e-01 | -0.0665 |
4502 | MT2A | CRC-3-11773 | Human | Colorectum | CRC | 6.73e-03 | -1.36e-01 | 0.2564 |
4502 | MT2A | AEH-subject3 | Human | Endometrium | AEH | 2.98e-09 | -3.59e-01 | -0.2576 |
4502 | MT2A | AEH-subject4 | Human | Endometrium | AEH | 4.21e-03 | -3.97e-01 | -0.2657 |
4502 | MT2A | EEC-subject1 | Human | Endometrium | EEC | 2.96e-07 | -4.13e-01 | -0.2682 |
4502 | MT2A | EEC-subject2 | Human | Endometrium | EEC | 1.13e-04 | -3.65e-01 | -0.2607 |
4502 | MT2A | EEC-subject3 | Human | Endometrium | EEC | 6.69e-13 | 6.84e-02 | -0.2525 |
4502 | MT2A | EEC-subject5 | Human | Endometrium | EEC | 2.68e-03 | -2.84e-01 | -0.249 |
4502 | MT2A | GSM5276934 | Human | Endometrium | EEC | 1.50e-05 | 4.33e-01 | -0.0913 |
4502 | MT2A | GSM5276937 | Human | Endometrium | EEC | 7.71e-11 | 5.68e-01 | -0.0897 |
4502 | MT2A | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.12e-10 | -1.31e-01 | -0.1869 |
4502 | MT2A | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 3.59e-12 | 1.14e-01 | -0.1875 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00100389 | Breast | Precancer | response to metal ion | 47/1080 | 373/18723 | 3.88e-07 | 1.79e-05 | 47 |
GO:00987548 | Breast | Precancer | detoxification | 24/1080 | 152/18723 | 6.49e-06 | 1.81e-04 | 24 |
GO:00466868 | Breast | Precancer | response to cadmium ion | 14/1080 | 68/18723 | 2.74e-05 | 6.21e-04 | 14 |
GO:00096368 | Breast | Precancer | response to toxic substance | 31/1080 | 262/18723 | 1.18e-04 | 2.12e-03 | 31 |
GO:00550767 | Breast | Precancer | transition metal ion homeostasis | 20/1080 | 138/18723 | 1.28e-04 | 2.24e-03 | 20 |
GO:00469165 | Breast | Precancer | cellular transition metal ion homeostasis | 17/1080 | 115/18723 | 3.15e-04 | 4.49e-03 | 17 |
GO:00712767 | Breast | Precancer | cellular response to cadmium ion | 9/1080 | 40/18723 | 3.69e-04 | 5.03e-03 | 9 |
GO:00712488 | Breast | Precancer | cellular response to metal ion | 24/1080 | 197/18723 | 4.35e-04 | 5.79e-03 | 24 |
GO:00712418 | Breast | Precancer | cellular response to inorganic substance | 26/1080 | 226/18723 | 6.23e-04 | 7.78e-03 | 26 |
GO:00975017 | Breast | Precancer | stress response to metal ion | 5/1080 | 19/18723 | 3.73e-03 | 3.04e-02 | 5 |
GO:00100435 | Breast | Precancer | response to zinc ion | 9/1080 | 58/18723 | 5.67e-03 | 4.08e-02 | 9 |
GO:0072503 | Breast | Precancer | cellular divalent inorganic cation homeostasis | 42/1080 | 486/18723 | 5.91e-03 | 4.21e-02 | 42 |
GO:001003814 | Breast | IDC | response to metal ion | 65/1434 | 373/18723 | 2.95e-10 | 3.42e-08 | 65 |
GO:004668613 | Breast | IDC | response to cadmium ion | 19/1434 | 68/18723 | 4.97e-07 | 2.45e-05 | 19 |
GO:000963613 | Breast | IDC | response to toxic substance | 44/1434 | 262/18723 | 6.33e-07 | 3.00e-05 | 44 |
GO:009875413 | Breast | IDC | detoxification | 29/1434 | 152/18723 | 3.97e-06 | 1.43e-04 | 29 |
GO:007127613 | Breast | IDC | cellular response to cadmium ion | 11/1434 | 40/18723 | 1.48e-04 | 2.60e-03 | 11 |
GO:005507613 | Breast | IDC | transition metal ion homeostasis | 23/1434 | 138/18723 | 3.20e-04 | 4.79e-03 | 23 |
GO:001004311 | Breast | IDC | response to zinc ion | 13/1434 | 58/18723 | 3.59e-04 | 5.18e-03 | 13 |
GO:004691612 | Breast | IDC | cellular transition metal ion homeostasis | 20/1434 | 115/18723 | 4.35e-04 | 5.90e-03 | 20 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0497812 | Breast | IDC | Mineral absorption | 13/867 | 60/8465 | 6.73e-03 | 3.42e-02 | 2.56e-02 | 13 |
hsa0497813 | Breast | IDC | Mineral absorption | 13/867 | 60/8465 | 6.73e-03 | 3.42e-02 | 2.56e-02 | 13 |
hsa0497821 | Breast | DCIS | Mineral absorption | 13/846 | 60/8465 | 5.48e-03 | 2.81e-02 | 2.07e-02 | 13 |
hsa0497831 | Breast | DCIS | Mineral absorption | 13/846 | 60/8465 | 5.48e-03 | 2.81e-02 | 2.07e-02 | 13 |
hsa0497814 | Prostate | BPH | Mineral absorption | 20/1718 | 60/8465 | 1.22e-02 | 3.61e-02 | 2.23e-02 | 20 |
hsa0497815 | Prostate | BPH | Mineral absorption | 20/1718 | 60/8465 | 1.22e-02 | 3.61e-02 | 2.23e-02 | 20 |
hsa049782 | Stomach | CAG with IM | Mineral absorption | 12/640 | 60/8465 | 1.52e-03 | 1.01e-02 | 7.10e-03 | 12 |
hsa049783 | Stomach | CAG with IM | Mineral absorption | 12/640 | 60/8465 | 1.52e-03 | 1.01e-02 | 7.10e-03 | 12 |
hsa049784 | Stomach | CSG | Mineral absorption | 11/633 | 60/8465 | 4.40e-03 | 2.53e-02 | 1.82e-02 | 11 |
hsa049785 | Stomach | CSG | Mineral absorption | 11/633 | 60/8465 | 4.40e-03 | 2.53e-02 | 1.82e-02 | 11 |
hsa049786 | Stomach | CAG | Mineral absorption | 8/368 | 60/8465 | 4.18e-03 | 2.94e-02 | 2.36e-02 | 8 |
hsa049787 | Stomach | CAG | Mineral absorption | 8/368 | 60/8465 | 4.18e-03 | 2.94e-02 | 2.36e-02 | 8 |
hsa049788 | Stomach | SIM | Mineral absorption | 11/465 | 60/8465 | 3.61e-04 | 3.41e-03 | 2.74e-03 | 11 |
hsa049789 | Stomach | SIM | Mineral absorption | 11/465 | 60/8465 | 3.61e-04 | 3.41e-03 | 2.74e-03 | 11 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MT2A | SNV | Missense_Mutation | c.17N>T | p.Ser6Phe | p.S6F | P02795 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | |
MT2A | SNV | Missense_Mutation | c.41N>T | p.Thr14Ile | p.T14I | P02795 | protein_coding | tolerated(0.13) | benign(0.121) | TCGA-D1-A0ZS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MT2A | SNV | Missense_Mutation | rs149120520 | c.158C>T | p.Ala53Val | p.A53V | P02795 | protein_coding | deleterious(0.04) | benign(0.14) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
MT2A | SNV | Missense_Mutation | novel | c.161C>T | p.Ser54Leu | p.S54L | P02795 | protein_coding | tolerated(0.16) | benign(0.001) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MT2A | SNV | Missense_Mutation | novel | c.28N>T | p.Gly10Cys | p.G10C | P02795 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-05-4424-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | erlotinib | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4502 | MT2A | NA | PARACETAMOL | ACETAMINOPHEN | 9570328 | |
4502 | MT2A | NA | ETHANOL | ALCOHOL | 1733046 |
Page: 1 |